Literature DB >> 29622161

Elevated Cardiac Troponin T in Patients With Skeletal Myopathies.

Johannes Schmid1, Laura Liesinger2, Ruth Birner-Gruenberger2, Tatjana Stojakovic3, Hubert Scharnagl3, Benjamin Dieplinger4, Martin Asslaber5, Roman Radl6, Meinrad Beer7, Malgorzata Polacin7, Johannes Mair8, Dieter Szolar9, Andrea Berghold10, Stefan Quasthoff11, Josepha S Binder12, Peter P Rainer13.   

Abstract

BACKGROUND: Cardiac troponins are often elevated in patients with skeletal muscle disease who have no evidence of cardiac disease.
OBJECTIVES: The goal of this study was to characterize cardiac troponin concentrations in patients with myopathies and derive insights regarding the source of elevated troponin T measurements.
METHODS: Cardiac troponin T (cTnT) and cardiac troponin I (cTnI) concentrations were determined by using high sensitivity assays in 74 patients with hereditary and acquired skeletal myopathies. Patients underwent comprehensive cardiac evaluation, including 12-lead electrocardiogram, 24-h electrocardiogram, cardiac magnetic resonance imaging, and coronary artery computed tomography. cTnT and cTnI protein expression was determined in skeletal muscle samples of 9 patients and in control tissues derived from autopsy using antibodies that are used in commercial assays. Relevant Western blot bands were subjected to liquid chromatography tandem mass spectrometry for protein identification.
RESULTS: Levels of cTnT (median: 24 ng/l; interquartile range: 11 to 54 ng/l) were elevated (>14 ng/l) in 68.9% of patients; cTnI was elevated (>26 ng/l) in 4.1% of patients. Serum cTnT levels significantly correlated with creatine kinase and myoglobin (r = 0.679 and 0.786, respectively; both p < 0.001). Based on cTnT serial testing, 30.1% would have fulfilled current rule-in criteria for myocardial infarction. Noncoronary cardiac disease was present in 23%. Using cTnT antibodies, positive bands were found in both diseased and healthy skeletal muscle at molecular weights approximately 5 kDa below cTnT. Liquid chromatography tandem mass spectrometry identified the presence of skeletal troponin T isoforms in these bands.
CONCLUSIONS: Measured cTnT concentrations were chronically elevated in the majority of patients with skeletal myopathies, whereas cTnI elevation was rare. Our data indicate that cross-reaction of the cTnT immunoassay with skeletal muscle troponin isoforms was the likely cause.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiac troponin; myopathy; skeletal muscle

Mesh:

Substances:

Year:  2018        PMID: 29622161     DOI: 10.1016/j.jacc.2018.01.070

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  34 in total

1.  Cardiac Troponin T: The Impact of Posttranslational Modifications on Analytical Immunoreactivity in Blood up to the Excretion in Urine.

Authors:  Douwe de Boer; Alexander S Streng; William P T M van Doorn; Wim H M Vroemen; Otto Bekers; Will K W H Wodzig; Alma M A Mingels
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Remote ischaemic conditioning: defining critical criteria for success-report from the 11th Hatter Cardiovascular Workshop.

Authors:  R M Bell; M Basalay; H E Bøtker; S Beikoghli Kalkhoran; R D Carr; J Cunningham; S M Davidson; T J England; S Giesz; A K Ghosh; P Golforoush; A V Gourine; D J Hausenloy; G Heusch; B Ibanez; P Kleinbongard; S Lecour; K Lukhna; M Ntsekhe; M Ovize; A D Salama; G Vilahur; J M Walker; D M Yellon
Journal:  Basic Res Cardiol       Date:  2022-08-15       Impact factor: 12.416

3.  Duchenne muscular dystrophy patients: troponin leak in asymptomatic and implications for drug toxicity studies.

Authors:  Larry W Markham; Jonathan H Soslow; Aryaz Sheybani; Kim Crum; Frank J Raucci; William B Burnette
Journal:  Pediatr Res       Date:  2021-08-24       Impact factor: 3.756

Review 4.  Metabolic Pathway of Cardiospecific Troponins: From Fundamental Aspects to Diagnostic Role (Comprehensive Review).

Authors:  Aleksey M Chaulin
Journal:  Front Mol Biosci       Date:  2022-04-19

5.  Cardiac involvement in a cross-sectional cohort of myotonic dystrophies and other skeletal myopathies.

Authors:  Johannes Schmid; Meinrad Beer; Andrea Berghold; Tatjana Stojakovic; Hubert Scharnagl; Benjamin Dieplinger; Stefan Quasthoff; Josepha S Binder; Peter P Rainer
Journal:  ESC Heart Fail       Date:  2020-05-31

Review 6.  Evaluation of Molecularly Imprinted Polymers for Point-of-Care Testing for Cardiovascular Disease.

Authors:  Brian Regan; Fiona Boyle; Richard O'Kennedy; David Collins
Journal:  Sensors (Basel)       Date:  2019-08-09       Impact factor: 3.576

7.  TNNT2 Missplicing in Skeletal Muscle as a Cardiac Biomarker in Myotonic Dystrophy Type 1 but Not in Myotonic Dystrophy Type 2.

Authors:  Francesca Bosè; Laura Valentina Renna; Barbara Fossati; Giovanni Arpa; Valentina Labate; Valentina Milani; Annalisa Botta; Emanuele Micaglio; Giovanni Meola; Rosanna Cardani
Journal:  Front Neurol       Date:  2019-09-27       Impact factor: 4.003

Review 8.  Irreversible oxidative post-translational modifications in heart disease.

Authors:  Tamara Tomin; Matthias Schittmayer; Sophie Honeder; Christoph Heininger; Ruth Birner-Gruenberger
Journal:  Expert Rev Proteomics       Date:  2019-07-30       Impact factor: 4.250

Review 9.  Sex differences in ischemic heart disease and heart failure biomarkers.

Authors:  Kimia Sobhani; Diana K Nieves Castro; Qin Fu; Roberta A Gottlieb; Jennifer E Van Eyk; C Noel Bairey Merz
Journal:  Biol Sex Differ       Date:  2018-09-17       Impact factor: 5.027

10.  Post-exercise high-sensitivity troponin T levels in patients with suspected unstable angina.

Authors:  Gaetano Antonio Lanza; Erica Mencarelli; Veronica Melita; Antonio Tota; Maurizio Gabrielli; Filippo Sarullo; Chiara Cordischi; Annalisa Potenza; Silvia Cardone; Antonio De Vita; Antonio Bisignani; Laura Manfredonia; Giuseppa Caccamo; Giuseppe Vitale; Silvia Baroni; Mirca Antenucci; Filippo Crea; Francesco Franceschi
Journal:  PLoS One       Date:  2019-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.